Literature DB >> 32240378

Facilitated completion of 1-year adjuvant S-1 monotherapy for pathological stage II or III gastric cancer by medical oncologists.

Yosuke Kano1, Manabu Ohashi2, Naoki Hiki3, Daisuke Takahari4, Keisho Chin4, Kensei Yamaguchi4, Satoshi Ida1, Koshi Kumagai1, Takeshi Sano1, Souya Nunobe1.   

Abstract

PURPOSE: Several factors are known to be significantly associated with a low completion rate of 1-year adjuvant S-1 monotherapy for gastric cancer. The present study investigated whether or not the specialties of physicians conducting adjuvant S-1 monotherapy affect the completion rate.
METHODS: A total of 437 patients who underwent curative gastrectomy followed by adjuvant S-1 monotherapy for pathological stage II or III gastric cancer between 2008 and 2013 were retrospectively analyzed. Factors affecting completion of adjuvant S-1 monotherapy, including the physicians (medical oncologists or surgeons) administering S-1, were evaluated by a multivariate analysis. The relationship between patient factors and physicians was analyzed regarding the cumulative incidence of discontinuation. The number of times the dose was reduced, the schedule changed, or administration was suspended or delayed in patients completing adjuvant S-1 monotherapy was also counted.
RESULTS: The multivariate analysis showed that old age (≥ 65 years old), excess body weight loss (≥ 15%), and surgeons were independently associated with discontinuation. In older patients, the cumulative incidence of discontinuation by medical oncologists was significantly lower than that by surgeons. Medical oncologists ensured that older patients continued S-1 by frequent suspension or a delay in each course.
CONCLUSIONS: Medical oncologists may facilitate completion of adjuvant S-1 monotherapy.

Entities:  

Keywords:  Adjuvant chemotherapy; Gastric cancer; S-1

Year:  2020        PMID: 32240378     DOI: 10.1007/s00595-020-01995-8

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  3 in total

1.  Cumulative total S-1 dose in adjuvant chemotherapy affects the long-term outcome following curative gastrectomy for gastric cancer.

Authors:  Keiji Nishibeppu; Shuhei Komatsu; Toshiyuki Kosuga; Takeshi Kubota; Kazuma Okamoto; Hirotaka Konishi; Atsushi Shiozaki; Hitoshi Fujiwara; Eigo Otsuji
Journal:  Am J Cancer Res       Date:  2021-05-15       Impact factor: 6.166

2.  The efficacy and toxicity of adjuvant S-1 schedule with 2-week administration followed by 1-week rest in gastric cancer patients.

Authors:  Yu-Yin Liu; Yueh-Wei Liu; Yen-Yang Chen; Shih-Ho Wang; Seng-Kee Chuah; Gong-Kai Huang; Yen-Hao Chen
Journal:  J Gastrointest Oncol       Date:  2021-04

3.  A prospective feasibility study of one-year administration of adjuvant S-1 therapy for resected biliary tract cancer in a multi-institutional trial (Tokyo Study Group for Biliary Cancer: TOSBIC01).

Authors:  Osamu Itano; Yusuke Takemura; Norihiro Kishida; Eiji Tamagawa; Hiroharu Shinozaki; Ken Ikeda; Hidejiro Urakami; Shigenori Ei; Shigeo Hayatsu; Keiichi Suzuki; Tadayuki Sakuragawa; Masatsugu Ishii; Masaya Shito; Koichi Aiura; Hiroto Fujisaki; Kiminori Takano; Junichi Matsui; Takuya Minagawa; Masahiro Shinoda; Minoru Kitago; Yuta Abe; Hiroshi Yagi; Go Oshima; Shutaro Hori; Yuko Kitagawa
Journal:  BMC Cancer       Date:  2020-07-23       Impact factor: 4.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.